Cumberland Pharmaceuticals financials
$7.65−0.91%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $166.5K | $9.1M | $13.7M | $8.3M | $380.8K | $11.7M | $10.4M | $9.1M | $9.8M | $8.5M | $9.4M | $10.1M |
| Gross profit | $166.5K | $7.2M | $11.4M | $7.3M | $380.8K | $10.3M | $8.5M | $7.8M | $8.1M | $6.9M | $7.8M | $8.3M |
| Gross margin | 100.0% | 78.8% | 83.6% | 88.1% | 100.0% | 87.8% | 81.1% | 85.4% | 82.6% | 81.5% | 83.6% | 82.5% |
| Operating income | -$3.2M | -$3.1M | -$1.4M | -$2.0M | -$3.1M | $1.3M | -$1.8M | -$1.7M | -$1.0M | -$1.9M | -$5.7M | -$1.5M |
| Net income | -$4.3M | -$3.3M | -$1.4M | -$1.9M | -$740.7K | $1.3M | -$1.9M | -$1.5M | -$1.1M | -$1.9M | -$6.3M | -$1.0M |
| Net margin | −2569.0% | −36.0% | −10.3% | −23.4% | −194.5% | 10.7% | −18.2% | −17.0% | −11.0% | −22.9% | −67.3% | −10.4% |
| Diluted EPS | $-0.29 | $-0.22 | $-0.10 | $-0.13 | $-0.05 | $0.08 | $-0.14 | $-0.11 | $-0.08 | $-0.14 | $-0.46 | $-0.07 |
| EBITDA | -$4.4M | -$1.9M | -$329.3K | -$927.5K | -$4.1M | $2.3M | -$345.6K | -$578.4K | $112.8K | -$718.6K | -$4.9M | -$620.5K |
| Operating cash flow | $168.7K | $387.0K | $3.0K | $187.2K | $843.8K | $3.9M | $1.9M | $475.5K | -$855.7K | -$2.1M | $2.3M | $1.2M |
| Free cash flow | $130.5K | $387.0K | $3.0K | $163.4K | $817.3K | $3.9M | $1.9M | $460.1K | -$862.8K | -$2.2M | $2.2M | $1.2M |
| Diluted shares | 15.0M | 15.0M | 14.2M | 15.0M | 15.0M | 15.3M | 14.0M | 14.1M | 14.1M | 14.1M | 13.8M | 14.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.9M | $11.0M | $11.4M | $15.2M | $16.1M | $15.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $5.2M | $5.2M | $5.2M | $5.2M | $5.2M |
| Total assets | $62.9M | $71.0M | $76.8M | $65.9M | $67.9M | $69.9M |
| Total liabilities | $45.8M | $49.7M | $52.3M | $40.1M | $40.2M | $41.6M |
| Shareholders' equity | $17.1M | $21.3M | $24.5M | $25.8M | $27.7M | $28.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology